PL Thomas Release: 5-LOXIN® Proven to Reduce the Symptoms of Osteoarthritis in New Human Study Published in Arthritis Research and Therapy

MORRISTOWN, N.J.--(BUSINESS WIRE)--PL Thomas (PLT), in alliance with Laila Nutraceuticals, India, today jointly announced the publication of a new study using their exclusive dietary supplement ingredient, 5-LOXIN®. In the study, 5-LOXIN supplementation conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily. Interestingly, significant improvements in pain score and functional ability were recorded in as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, a significant reduction in synovial fluid MMP activity, enzymes which damage connective tissue, was noted. 5-LOXIN was found to be well-tolerated, with no safety concerns. Arthritis Research & Therapy 2008, 10:R85doi:10.1186/ar2461.

MORE ON THIS TOPIC